E-viri
Recenzirano
Odprti dostop
-
Lang, Anthony E.; Siderowf, Andrew D.; Macklin, Eric A.; Poewe, Werner; Brooks, David J.; Fernandez, Hubert H.; Rascol, Olivier; Giladi, Nir; Stocchi, Fabrizio; Tanner, Caroline M.; Postuma, Ronald B.; Simon, David K.; Tolosa, Eduardo; Mollenhauer, Brit; Cedarbaum, Jesse M.; Fraser, Kyle; Xiao, James; Evans, Karleyton C.; Graham, Danielle L.; Sapir, Inbal; Inra, Jennifer; Hutchison, R. Matthew; Yang, Minhua; Fox, Tara; Budd Haeberlein, Samantha; Dam, Tien
New England journal of medicine/The New England journal of medicine, 08/2022, Letnik: 387, Številka: 5Journal Article
In a phase 2 trial in early Parkinson’s disease, treatment with cinpanemab, a monoclonal antibody to α-synuclein, did not affect clinical or imaging progression over a period of 72 weeks.
